Given the central role of CHK1 in DDR network signalling, the targeted inhibition of CHK1 provides various opportunities to achieve synthetic lethality in specific tumour genotypes; notably, in tumour cells exhibiting loss-of-function mutations in tumour protein 53 (TP53) or ATM or in other repair genes. This evidence concerns the gene ATM and neoplasm.